Literature DB >> 19556356

Selective inhibition of acetylcholine-evoked responses of alpha7 neuronal nicotinic acetylcholine receptors by novel tris- and tetrakis-azaaromatic quaternary ammonium antagonists.

Gretchen Y López-Hernández1, Jeffrey S Thinschmidt, Guangrong Zheng, Zhenfa Zhang, Peter A Crooks, Linda P Dwoskin, Roger L Papke.   

Abstract

A family of 20 tris-azaaromatic quaternary ammonium (AQA) compounds were tested for their inhibition of alpha7 nicotinic acetylcholine receptors (nAChRs) expressed in Xenopus laevis oocytes. The potency of inhibitory activity was related to the hydrophobic character of the tris head groups. Two tris-AQA compounds were studied in detail: the highly effective inhibitor 1,3,5-tri-[5-(1-quinolinum)-pent-1-yn-1-yl]-benzene tribromide (tPyQB) and the less potent antagonist 1,3,5,-tri-{5-[1-(2-picolinium)]-pent-1-yn-1-yl}benzene tribromide (tPy2PiB). In addition, we evaluated 1,2,4,5-tetra-{5-[1-(3-benzyl)pyridinium]pent-1-yl}benzene tetrabromide (tkP3BzPB), a tetrakis-AQA with very hydrophobic headgroups. We compared the activity of the AQA compounds to the frequently used alpha7-antagonist methyllycaconitine (MLA). Both tPyQB and tkP3BzPB were selective antagonists of alpha7. However, although inhibition by tPyQB was reversible within 5 min, the recovery time constant for tkP3BzPB inhibition was 26.6 +/- 0.8 min, so that the equilibrium inhibition in the prolonged presence of nanomolar concentrations of tkP3BzPB was nearly 100%. The potency, selectivity, and slow reversibility of tkP3BzPB were comparable with or greater than that of MLA. The inhibitory actions of tPyQB, tPy2PiB, and tkP3BzPB were evaluated on the acetylcholine (ACh)-evoked responses of native nAChRs in rat brain slices. The alpha7-mediated responses of hippocampal interneurons were effectively reduced by 1 microM tPyQB and tkP3BzPB but not tPy2PiB. In rat medial septum, tkP3BzPB produced a greater inhibition of ACh-evoked responses of cells with fast inward currents (type I) than of cells with predominantly slow kinetics (type II), suggesting that tkP3BzPB can block alpha7 yet preserve the responsiveness of non-alpha7 receptors. These agents might be helpful in elucidating complex receptor responses in brain regions with mixed populations of nAChRs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19556356      PMCID: PMC2730394          DOI: 10.1124/mol.109.056176

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  52 in total

1.  Nicotinic receptors on local circuit neurons in dentate gyrus: a potential role in regulation of granule cell excitability.

Authors:  Charles J Frazier; Ben W Strowbridge; Roger L Papke
Journal:  J Neurophysiol       Date:  2003-02-12       Impact factor: 2.714

2.  Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas.

Authors:  Huibert D Mansvelder; J Russel Keath; Daniel S McGehee
Journal:  Neuron       Date:  2002-03-14       Impact factor: 17.173

3.  alpha7 receptor-selective agonists and modes of alpha7 receptor activation.

Authors:  R L Papke; E Meyer; T Nutter; V V Uteshev
Journal:  Eur J Pharmacol       Date:  2000-03-30       Impact factor: 4.432

Review 4.  Nicotine addiction: the possible role of functional upregulation.

Authors:  Bruno Buisson; Daniel Bertrand
Journal:  Trends Pharmacol Sci       Date:  2002-03       Impact factor: 14.819

5.  Differential desensitization and distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas.

Authors:  Julian R A Wooltorton; Volodymyr I Pidoplichko; Ron S Broide; John A Dani
Journal:  J Neurosci       Date:  2003-04-15       Impact factor: 6.167

6.  N-n-alkylnicotinium analogs, a novel class of nicotinic receptor antagonists: interaction with alpha4beta2* and alpha7* neuronal nicotinic receptors.

Authors:  Lincoln H Wilkins; Vladimir P Grinevich; Joshua T Ayers; Peter A Crooks; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2003-01       Impact factor: 4.030

7.  Activation and desensitization of nicotinic alpha7-type acetylcholine receptors by benzylidene anabaseines and nicotine.

Authors:  Roger L Papke; William R Kem; Ferenc Soti; Gretchen Y López-Hernández; Nicole A Horenstein
Journal:  J Pharmacol Exp Ther       Date:  2009-02-17       Impact factor: 4.030

8.  Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis.

Authors:  Roger L Papke; Julia K Porter Papke
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

9.  Alternate stoichiometries of alpha4beta2 nicotinic acetylcholine receptors.

Authors:  Mark E Nelson; Alexander Kuryatov; Catherine H Choi; Yan Zhou; Jon Lindstrom
Journal:  Mol Pharmacol       Date:  2003-02       Impact factor: 4.436

10.  Methyllycaconitine is a potent antagonist of alpha-conotoxin-MII-sensitive presynaptic nicotinic acetylcholine receptors in rat striatum.

Authors:  Adrian J Mogg; Paul Whiteaker; J Michael McIntosh; Michael Marks; Allan C Collins; Susan Wonnacott
Journal:  J Pharmacol Exp Ther       Date:  2002-07       Impact factor: 4.030

View more
  13 in total

1.  Structure-activity relationship studies of sulfonylpiperazine analogues as novel negative allosteric modulators of human neuronal nicotinic receptors.

Authors:  Brandon J Henderson; Daniel J Carper; Tatiana F González-Cestari; Bitna Yi; Kiran Mahasenan; Ryan E Pavlovicz; Martin L Dalefield; Robert S Coleman; Chenglong Li; Dennis B McKay
Journal:  J Med Chem       Date:  2011-11-18       Impact factor: 7.446

2.  Multiple modes of α7 nAChR noncompetitive antagonism of control agonist-evoked and allosterically enhanced currents.

Authors:  Can Peng; Matthew R Kimbrell; Chengju Tian; Thomas F Pack; Peter A Crooks; E Kim Fifer; Roger L Papke
Journal:  Mol Pharmacol       Date:  2013-07-09       Impact factor: 4.436

3.  The novel small molecule α9α10 nicotinic acetylcholine receptor antagonist ZZ-204G is analgesic.

Authors:  Joseph R Holtman; Linda P Dwoskin; Cheryl Dowell; Elzbieta P Wala; Zhenfa Zhang; Peter A Crooks; J Michael McIntosh
Journal:  Eur J Pharmacol       Date:  2011-09-17       Impact factor: 4.432

Review 4.  Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.

Authors:  Dustin K Williams; Jingyi Wang; Roger L Papke
Journal:  Biochem Pharmacol       Date:  2011-05-14       Impact factor: 5.858

5.  Enhancement of attentional performance by selective stimulation of alpha4beta2(*) nAChRs: underlying cholinergic mechanisms.

Authors:  William M Howe; Jinzhao Ji; Vinay Parikh; Sarah Williams; Elisabeth Mocaër; Caryn Trocmé-Thibierge; Martin Sarter
Journal:  Neuropsychopharmacology       Date:  2010-02-10       Impact factor: 7.853

6.  Persistent activation of α7 nicotinic ACh receptors associated with stable induction of different desensitized states.

Authors:  Roger L Papke; Clare Stokes; M Imad Damaj; Ganesh A Thakur; Khan Manther; Millet Treinin; Deniz Bagdas; Abhijit R Kulkarni; Nicole A Horenstein
Journal:  Br J Pharmacol       Date:  2017-06-08       Impact factor: 8.739

Review 7.  Merging old and new perspectives on nicotinic acetylcholine receptors.

Authors:  Roger L Papke
Journal:  Biochem Pharmacol       Date:  2014-01-31       Impact factor: 5.858

8.  Defining the putative inhibitory site for a selective negative allosteric modulator of human α4β2 neuronal nicotinic receptors.

Authors:  Brandon J Henderson; Tatiana F González-Cestari; Bitna Yi; Ryan E Pavlovicz; R Thomas Boyd; Chenglong Li; Stephen C Bergmeier; Dennis B McKay
Journal:  ACS Chem Neurosci       Date:  2012-05-25       Impact factor: 4.418

9.  Discovery of non-peptide, small molecule antagonists of α9α10 nicotinic acetylcholine receptors as novel analgesics for the treatment of neuropathic and tonic inflammatory pain.

Authors:  Guangrong Zheng; Zhenfa Zhang; Cheryl Dowell; Elzbieta Wala; Linda P Dwoskin; Joseph R Holtman; J Michael McIntosh; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2011-02-23       Impact factor: 2.823

10.  Discovery of novel alpha7 nicotinic receptor antagonists.

Authors:  Youyi Peng; Qiang Zhang; Gretchen L Snyder; Hongwen Zhu; Wei Yao; John Tomesch; Roger L Papke; James P O'Callaghan; William J Welsh; Lawrence P Wennogle
Journal:  Bioorg Med Chem Lett       Date:  2010-06-25       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.